¼¼°è ÆéƼµå ¹× ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå CDMO ½ÃÀå : ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ - Á¦Ç° À¯Çüº°, ¼­ºñ½º À¯Çüº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2030³â)
Peptide And Oligonucleotide CDMO Market Size, Share & Trends Analysis Report By Product (Peptides, Oligonucleotides), By Service Type, By End Use (Pharmaceutical Companies, Biopharmaceutical Companies), By Region, And Segment Forecasts, 2024 - 2030
»óǰÄÚµå : 1433686
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2024³â 01¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 195 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,263,000
Unprintable PDF & Excel (Single User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» 1Àθ¸ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,950 £Ü 9,652,000
Printable PDF & Excel (5-User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ ºÎ¼­¿¡¼­ ÃÖ´ë 5¸í±îÁö »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,429,000
Printable PDF & Excel (Enterprise License) help
º¸°í¼­ ±¸¸Å ±â¾÷ ¹× ±× ÀÚȸ»ç, °ü°è»ç°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀ̸ç, PDF ¹× ¿¢¼¿ ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ÆéƼµå ¹× ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå CDMO ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :

Grand View ResearchÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°è ÆéƼµå ¹× ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå CDMO ½ÃÀåÀº 2030³â±îÁö 56¾ï 7,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

2024³âºÎÅÍ 2030³â±îÁö º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 12.5%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù. ÆéƼµå ¹× ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå°¡ ´Ù¾çÇÑ Áúº´¿¡ ´ëÇÑ ±ÍÁßÇÑ Ä¡·áÁ¦·Î Àνĵǰí ÀÖ´Â °ÍÀº CDMO ¼­ºñ½º ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÆéƼµå ¹× ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå Ä¡·áÁ¦ÀÇ ÆÄÀÌÇÁ¶óÀÎÀÌ Áõ°¡Çϰí ÀÖ´Â °Í, ÀÌ ºÐ¾ß¿¡¼­ÀÇ CDMOÀÇ Ä§Åõ°¡ ÁøÇàµÇ°í ÀÖ´Â °Íµµ, ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀÇ Çϳª°¡ µÇ°í ÀÖ½À´Ï´Ù.

½ÃÀåÀº ´ÜÆíÈ­µÇ°í ÀÖÀ¸¸ç, ¿©·¯ ±â¾÷ÀÌ ¸¶Âù°¡Áö·Î ±â¼ú·Â°ú °¡°ø ´É·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ÀÌ È¸»çµéÀº ÆéƼµå ¹× ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå °³¹ß, µ¥ÀÌÅÍ ºÐ¼®, »ùÇà ºÐ¼®, ÀÓ»ó½ÃÇè Áö¿ø µî ´Ù¾çÇÑ ¼­ºñ½º¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ ½ÃÀåÀº ǰÁú º¸Áõ, ±â¼ú Áøº¸, ±ÔÁ¦¿¡ ´ëÀÀ, °í°¡Ä¡·Î ´Ù¾çÇÑ ¼­ºñ½º¸¦ Á¦°øÇÏ´Â ´É·Â µî ¿äÀο¡ ÀÇÇÑ Ä¡¿­ÇÑ °æÀïÀÌ Æ¯Â¡ÀÔ´Ï´Ù.

ÆéƼµå ¹× ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå¸¦ ±â¹ÝÀ¸·Î ÇÏ´Â Ä¡·áÁ¦ÀÇ °³¹ß,Á¦Á¶¿¡ À־ÀÇ ´ë±â¾÷¿¡ ÀÇÇÑ ÅõÀÚÀÇ È®´ë´Â ½ÃÀåÀÇ ¼ºÀåÀ» ÁöÁöÇÏ´Â ÇöÀúÇÑ ¿äÀÎÀÇ ÇϳªÀÔ´Ï´Ù. ¿¹¸¦ µé¾î 2023³â 9¿ù, CordenPharma»ç´Â CordenPharma Colorado»çÀÇ ¼³ºñ Áõ°­¿¡ ÀÇÇÑ »ó¾÷¿ë ÆéƼµå »ý»ê ´É·ÂÀÇ È®´ë¸¦ ¹ßÇ¥Çϰí, ÇöÀç ¼¼°è ÃÖ´ëÀÇ °í»ó ÆéƼµå ÇÕ¼º(SPPS) Á¦Á¶ ½Ã¼³ÀÌ µÇ°í ÀÖ½À´Ï´Ù. °Ô´Ù°¡ 2023³â 9¿ù, CombiGeneÀº AmbioPharmÀ» Zyneyroµµ °ü¿©ÇÏ´Â ÆéƼµå ±â¹Ý ÅëÁõ ÇÁ·ÎÁ§Æ® COZY01ÀÇ CDMO ÆÄÆ®³Ê·Î ¼±Á¤Çß½À´Ï´Ù.

COVID-19ÀÇ À¯ÇàÀº ½ÃÀå¿¡ Áß°£ Á¤µµÀÇ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. COVID-19 ÆÒµ¥¹ÍÀÇ Ãʱ⠴ܰè´Â ¿©Çà Á¦ÇÑ, °ø±Þ¸Á È¥¶õ, ÀÓ»ó½ÃÇè ÈÄÅð µîÀÇ °á°ú·Î ÀÓ»ó½ÃÇè¿¡ ÇöÀúÇÑ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ±×·³¿¡µµ ºÒ±¸Çϰí Ç×¹ÙÀÌ·¯½º ÆéƼµå°¡ Á߽õǰí mRNA ¹é½ÅÀÌ ½Å¼ÓÇÏ°Ô °³¹ßµË´Ï´Ù. ¶ÇÇÑ ÆéƼµå ±â¹Ý Ä¡·áÁ¦ »ý»êÀ» ÃËÁøÇϱâ À§ÇØ ¹ÙÀÌ¿À ÀǾàǰ ±â¾÷ °£ Çù·Â°ú Á¦ÈÞ°¡ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

ÆéƼµå ¹× ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå CDMO ½ÃÀå º¸°í¼­, ÇÏÀ̶óÀÌÆ®

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ÆéÆ¼µå ¹× ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå CDMO ½ÃÀå º¯¼ö, µ¿Çâ ¹× ¹üÀ§

Á¦4Àå ÆéÆ¼µå ¹× ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå CDMO ½ÃÀå : Á¦Ç° ÃßÁ¤,µ¿Ç⠺м®

Á¦5Àå ÆéÆ¼µå ¹× ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå CDMO ½ÃÀå : ¼­ºñ½º À¯ÇüÀÇ ÃßÁ¤,µ¿Ç⠺м®

Á¦6Àå ÆéÆ¼µå ¹× ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå CDMO ½ÃÀå : ÃÖÁ¾ ¿ëµµÀÇ ÃßÁ¤,µ¿Ç⠺м®

Á¦7Àå ÆéÆ¼µå ¹× ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå CDMO ½ÃÀå :Áö¿ª ÃßÁ¤,µ¿Ç⠺м®

Á¦8Àå °æÀï ±¸µµ

BJH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Peptide And Oligonucleotide CDMO Market Growth & Trends:

The global peptide and oligonucleotide CDMO market is expected to reach USD 5.67 billion by 2030, according to a new report by Grand View Research, Inc. , registering a CAGR of 12.5% from 2024 to 2030. The growing recognition of peptides and oligonucleotides as valuable therapeutic agents for various diseases is fueling the demand for CDMO services. Moreover, the increasing pipeline of peptides and oligonucleotide therapeutics and the growing penetration of CDMOs in the field are a few of the factors driving the growth of the market.

The market is fragmented, with several players having similar technological and processing capabilities. These companies offer various services related to peptide and oligonucleotide development, data interpretation, sample analysis, and clinical trial support. The market is characterized by fierce competition driven by factors such as quality assurance, technological advancements, regulatory compliance, and the ability to offer high-value and diverse services.

The growing investment by major companies in the development and manufacturing of peptides and oligonucleotide-based therapeutics is one of the prominent factors supporting the growth of the market. For instance, in September 2023, CordenPharma announced the expansion of its commercial peptide production capabilities through the enhancement of facilities at CordenPharma Colorado, which now stands as the world's largest Solid-Phase Peptide Synthesis (SPPS) manufacturing facility. Additionally, in September 2023, CombiGene selected AmbioPharm as the CDMO partner for their peptide-based pain project, COZY01, which also involves Zyneyro.

The COVID-19 pandemic moderately impacted the market. The early stages of the COVID-19 pandemic had a notable impact on clinical trials, as a result of travel restrictions, disruptions in the supply chain, and setbacks in clinical trials. Nonetheless, it also presented prospects, notably the heightened emphasis on antiviral peptides and the swift creation of mRNA vaccines. Furthermore, there has been a substantial increase in collaborations and partnerships across biopharmaceutical companies with an aim to boost the production of peptide-based therapeutics.

Peptide And Oligonucleotide CDMO Market Report Highlights:

Table of contents

Chapter 1. Research Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Peptide and Oligonucleotide CDMO Market Variables, Trends & Scope

Chapter 4. Peptide and Oligonucleotide CDMO Market: Product Estimates & Trend Analysis

Chapter 5. Peptide and Oligonucleotide CDMO Market: Service Type Estimates & Trend Analysis

Chapter 6. Peptide and Oligonucleotide CDMO Market: End Use Estimates & Trend Analysis

Chapter 7. Peptide and Oligonucleotide CDMO Market: Regional Estimates & Trend Analysis

Chapter 8. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â